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Abstract: The type I interferon response protects cells against invad-
ing viral pathogens. The cellular factors that mediate this defense are
the products of interferon-stimulated genes (ISGs). Although hun-
dreds of ISGs have been identiﬁed since their discovery more than
25 years ago, only a few have been characterized with respect to
antiviral activity. For most ISG products, little is known about their
antiviral potential, their target speciﬁcity, and their mechanisms of
action. Using an overexpression screening approach, here we show
that different viruses are targeted by unique sets of ISGs. We ﬁnd that
each viral species is susceptible to multiple antiviral genes, which
together encompass a range of inhibitory activities. To conduct the
screen, more than 380 human ISGs were tested for their ability to
inhibit the replication of several important human and animal
viruses, including hepatitis C virus, yellow fever virus, West Nile
virus, chikungunya virus, Venezuelan equine encephalitis virus, and
human immunodeﬁciency virus type-1. Broadly acting effectors
included IRF1, C6orf150 (also known as MB21D1), HPSE, RIG-I (also
known as DDX58), MDA5 (also known as IFIH1), and IFITM3,
whereas more targeted antiviral speciﬁcity was observed with
DDX60, IFI44L, IFI6, IFITM2, MAP3K14, MOV10, NAMPT (also known
as PBEF1), OASL, RTP4, TREX1, and UNC84B (also known as SUN2).
Combined expression of pairs of ISGs showed additive antiviral
effects similar to those of moderate type I interferon doses. Mecha-
nistic studies uncovered a common theme of translational inhibition
for numerous effectors. Several ISGs, including ADAR, FAM46C,
LY6E, and MCOLN2, enhanced the replication of certain viruses,Journal of Hepatology 20
Received 19 July 2011; accepted 20 July 2011
⇑ Corresponding author. Address: INSERM U773, CRB3, Hôpital Beaujon, 100
Boulevard du Général Leclerc, 92110 Clichy, France. Tel.: +33 1 40 87 55 21; fax:
+33 1 47 37 05 33.
E-mail address: tarik.asselah@bjn.aphp.fr (T. Asselah).highlighting another layer of complexity in the highly pleiotropic
type I interferon system.
 2011 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Introduction
Type I interferons are a family of major innate immune cytokines
produced by host cells in response to viral infection [1]. Since their
discovery 50 years ago, fundamental and biomedical research has
greatly improved our understanding of their molecular mecha-
nisms of action, and led to the development of the ﬁrst ‘‘cyto-
kine-based’’ therapy in the 70s, now licensed worldwide for
viral disease, malignant and even immune disorders [1,2].
Interferon remains the therapeutic backbone of chronic hepa-
titis C. The standard of care, in HCV genotype 1 infected patients,
is the addition of direct-acting antivirals (DAAs) with a protease
inhibitor (telaprevir or boceprevir) to pegylated interferon plus
ribavirin [3].
The type I interferon family is composed of 5 members in
humans: the well described IFNa and IFNb, along with IFNj, IFNe,
IFNx that are less characterized, and more tissue targeted [4,5].
There are 13 IFNa and one IFNb isoforms, all acting through a
unique ubiquitous heterodimeric receptor IFNAR1/IFNAR2. Down-
stream signaling pathways have been extensively described:
phosphorylation of tyrosine kinases JAK1 and TYK2 results in the
recruitment of STAT1 and STAT2 which migrate into the nucleus
and associate with IFN regulatory factor 9 (IRF9) to form the IFN-
stimulated gene factor 3 (ISGF3). This complex then activates the
transcription of all the IFN StimulatedGenes (ISGs),whichmediate
diverse cellular effects in the infected cell. The study of highly
induced ISGs (MX1, OAS, dsRNA-activated protein kinase PKR)
led to fundamental discoveries concerning the translational con-
trol and regulation of RNA stability [6].Unresolved questions
The function of many ISGs, however, remains unknown, limiting
our ability to manipulate IFN in a rational manner and predict its































Fig. 1. New view of ISG’s function in viral replication. Interferon stimulated genes (ISG) can be divided in 3 groups: strong inhibitors, modest inhibitors or enhancers. ISGs
use multiple strategies to inhibit viral replication: either by targeting speciﬁc phase of viral replication (e.g. primary translational inhibition) or/and by potentiating IFN
response by a positive feedback loop. IFNAR, Interferon receptor; ISRE, Interferon response stimulating elements, IRF9, Interferon response factor 9.
JOURNAL OF HEPATOLOGYwhether all ISGs share the same antiviral potential and/or mech-
anism of action.
In the issue of April 2011 of Nature, Schoggins and colleagues
succeeded in answering these questions [7]. They proposed a new
model to analyze the antiviral function of ISG in a systematic and
large-scale manner. They developed a cell-based assay using a
lentiviral vector co-expressing an ISG and a red ﬂuorescent pro-
tein, TagRFP, in order to overexpress the ISG in different cell
types. They subsequently challenged these cells with different
green ﬂuorescent proteins (GFP)-expressing viruses (including
HCV) to assess the inhibitory capacity of all the ISG on viral rep-
lication by ﬂow cytometry.
Interestingly, they identiﬁed 3 main categories of ISGs for
each virus: a small group with strong inhibitory effect that prob-
ably has a feedback into the IFN-mediated signaling pathway; a
major group with moderate inhibitory functions, and a small
group that surprisingly enhances viral replication. Moreover,
the use of combinations of two inhibitory ISGs increased the
inhibition to 90% for HCV, HIV, and yellow fever virus
replication.
Nucleic acid binding, hydrolase, and helicase activities were
the main molecular functions of the ISG. The authors then inves-
tigated the potential mechanism of action of selected inhibitory
ISGs. Translational inhibition appears to be a common mecha-
nism of ISG-mediated antiviral effect which correlates with per-
cent of inhibition. In the case of HCV, IRF1, IRF2, IRF7 MDA5,
RIG-I, MAP3K14, and OASL were the most efﬁcient ISG and inhib-
ited primary translation by 25–70% after 4 h of infection. None of
them was able to signiﬁcantly impair viral entry into the cell.
These results support the concept that the downstream effec-
tors of Type I interferon exploit multiple strategies to block viralJournal of Hepatology 201replication at an early stage, in an additive manner. Some of the
ISGs, however, have the paradoxical effect of enhancing viral rep-
lication at least in this experimental model.Novelty of this article
This is the ﬁrst study on IFN downstream effectors to screen such
large numbers of ISGs (380) in a systematic manner. Moreover,
the reported ﬁndings point out new differences between ISGs
in terms of viral replication and mechanism of action, which
change our current view of ISG function (Fig. 1).
Some ISGs have broad effects on different viruses (IRF1,
C6orf150, RIG-1, MDA5) whereas others are more target-speciﬁc
(IFI44l, IFI6, OASL, IFIT3M). Even if they don’t share the same
mechanism of action, they can have additive effects to maximize
viral inhibition. Capacity of viral inhibition varies among ISGs,
and the authors showed for the ﬁrst time that few of them could
indeed enhance viral replication. It would be interesting now to
test the ISGs on other viruses in order to have a complete view
of ISGs functions.Perspectives, unanswered questions
An important question remains whether the in vitro over-expres-
sion of the ISGs reﬂects in vivo expression. It is crucial to validate
the targeted set of ISGs on in vivo or ex vivo samples. To date, sev-
eral studies on liver gene expression in chronic hepatitis C have
already identiﬁed a type I interferon signature (MX1, OAS1,
IFI27, viperin) [8–11]. None of these molecules appear to have a2 vol. 56 j 726–728 727
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strong ‘‘inhibitory potential’’ for HCV replication according to the
Shoggins study. Interestingly, in chronic hepatitis C, prior to the
initiation of treatment, gene expression proﬁles differ between
non-responders and responders. The most notable changes in
gene expression are mainly observed in the IFN stimulated genes
[12]. A two-gene signature (IFI27 and CXCL9) was able to predict
treatment response. Interestingly, the baseline liver levels of
expression of IFN stimulated genes were higher in non-respond-
ers than in sustained virological responders. The failure to
respond to exogenous PEG-IFN in non-responders could indicate
a blunted response to IFN. This suggests that IFN stimulated
genes are already maximally induced in non-responders.
Furthermore, it seems also that some ISGs can enhance HCV
replication but these were not described in details. Another par-
adoxical ﬁnding is that HCV through NS3-4A expression may
inhibit the RIG-1 and MDA pathway that was found to be the
most efﬁcient inhibitor of HCV replication [13]. Follow up studies
are necessary to extend and validate the Schoggins’ ﬁndings in
complementary model systems, as well as on patient material.Conclusions
In their study, Schoggins and colleagues bring new insight into the
effector mechanisms of type I IFN responses. The understanding of
antiviral mechanisms of IFN is crucial for the discovery of new treat-
ment biomarkers for efﬁcacy and toxicity. Moreover, there is a need
for improvement of IFN therapywith regard to the clinical side effect
and viral resistance. Focus on speciﬁc sets of ISGs could lead to the
development of a more targeted therapy, by speciﬁcally inhibiting
viral replication, while diminishing the side effects observed with
type I IFNs. Future investigation and therapeutic clinical trials will
be crucial to validate the potential of using ISGs in vivo.Conﬂict of interest
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